Primary Site >> Colorectal Cancer

Gene >> EGFL7

  • 2008
  • 2011
  • 2013
  • 2014
  • 2015
  • 2017
  • 2018
Ref: Deregulated expression of miR-106a predicts survival in human colon cancer patients.
PMID: 18521848
Ref: Down-regulation of EGFL8: a novel prognostic biomarker for patients with colorectal cancer.
PMID: 21737648
Ref: The expression of Egfl7 in human normal tissues and epithelial tumors.
PMID: 23558933
Ref: Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer.
PMID: 23900443
Ref: Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis.
PMID: 24815445
Ref: Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study.
PMID: 25592646
Ref: Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab.
PMID: 28539619
Ref: Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
PMID: 29438092
Ref: Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
PMID: 29636300
Ref: EGFL7: Master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis.
PMID: 29923200